Shares tumbled to $46.83 in pre-market trading, erasing a week of gains in a single session as Novo Nordisk signaled that its U.S. obesity-drug business is decelerating faster than investors hoped. With official Q2 results not due until August 5, the early disclosure — weaker numbers and a downward revision to full-year expectations — suggests management saw no point in letting the bad news fester.
The U.S. Growth Engine Is Sputtering at the Worst Possible Time. Management has cited slowing GLP-1 prescription trends, intensifying competition from Eli Lilly, and pricing pressure tied to the Trump administration's most-favored-nation pricing agreement as the core drags on the U.S. business. Reduced Medicaid obesity coverage and weaker prescription trends for injectable GLP-1 drugs continue to create significant operational hurdles. This matters because the U.S. accounts for the bulk of Novo's obesity revenue, and any slowdown there cascades directly into earnings.
A Year of Guidance Cuts Has Shredded Credibility. The company initially guided for adjusted sales and operating profit to fall 5% to 13% this year.
After Q1, it narrowed that to a 4% to 12% decline. Now another downward revision arrives before Q2 even posts. Analysts were projecting Q2 earnings per share of $0.82, already a 15.5% decline from the prior year. Repeated guidance reductions erode the market's willingness to pay a premium for future growth.
The Wegovy Pill Is Growing — But Not Fast Enough to Offset Price Erosion. The oral version of its flagship weight-loss drug generated $2.26 billion in its first quarter and captured 65% of new U.S. prescriptions. Yet planned list-price cuts of roughly 50% for Wegovy and 35% for Ozempic, effective January 2027, will compress cash flow even as volumes rise. While rival Eli Lilly guided to 25% sales growth for 2026, Novo forecast declines of up to 13% — a gap that keeps widening.
The Stock Is Cheap, But "Cheap" Hasn't Been Enough. Novo trades at a forward price-to-earnings ratio of roughly 14 with a 62% operating margin and 71% return on equity — metrics that would normally attract bargain hunters. But the company's market value has fallen roughly 70% from its June 2024 peak , and each guidance cut resets the floor lower. Until investors see stable U.S. volumes and pricing, the valuation discount is more trap than opportunity.